Market Report Source

Overview

Introduction
The ageing of the population will result in an increased incidence of coronary artery disease, heart failure and stroke. In addition to these epidemiological forces, the antithrombotics market will be sustained by the forthcoming launch of innovative novel agents whose sales revenue is expected to dampen the commercial impact of generic incursion in blockbuster proceeds.

Scope
Country specific event-driven sales forecasts for the period 2006-15 for the US, Japan, France, Germany, Italy, Spain and the UK
Discussion of recent trials and market-shaping future key events
Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and class switching
Case studies evaluating the commercial impact of two developmental agents with blockbuster potential

Highlights
Demographic trends lead to an increase in the patient population requiring antithrombotic therapy. However, the rising age of the population across all developed regions is increasing the fiscal burden on healthcare payors which are likely to respond by limiting the reimbursement potential of therapies and put pricing pressure on all agents.

The highest selling brands in the antidiabetics market are Lovenox (enoxaparin) and Plavix (clopidogrel), but these agents are subject to forthcoming genericization and will thus not contribute to the growth of the antithrombotics market in the medium-to-long term. Pipeline agents are expected to become significant drivers in the market.

The antithrombotics market is characterized by pockets of high unmet need and a broad spectrum of similarly efficacious therapeutic strategies. There is regional bias in the choice and popularity of therapeutic strategies driven by cultural reasons as well as infrastructural confines.

Reasons to Purchase
Quantify future size and scope of the antithrombotics market and potential for new products
Analyze options to expand commercial potential through pursuit of new indications
Formulate successful launch strategies in a highly competitive mature market

Table of Contents

CHAPTER 1 EXECUTIVE SUMMARY

Objective of the analysis

Datamonitor insight into the antithrombotics market

CHAPTER 2 MARKET DEFINITION AND OVERVIEW

Market definition for this report

Current market situation

Antithrombotics market: overview

Anticoagulants market

Heparins

Low molecular weight heparin (LMWH)

Parenteral non-heparinoid anticoagulants

Oral anticoagulants

Antiplatelets market

ADP receptor antagonists

cAMP enhancing platelet aggregation inhibitors

GP 2b/3a inhibitors

Other antiplatelets

Thrombolytics market

National markets

Anticoagulants

Antiplatelets

Thrombolytics

Key clinical trials

Key clinical trials in the anticoagulant category

Lovenox (enoxaparin)

Angiomax (bivalirudin)

Arixtra (fondaparinux)

Key clinical trials in the antiplatelet category

Plavix (clopidogrel)

Key clinical trials in the thrombolytics category

TNK (tenecteplase)

Actilyse (tPA, alteplase)

CHAPTER 3 COUNTRY MARKET ASSESSMENTS

Current and future opportunities and threats in the antithrombotics market

Global opportunities and threats

Opportunity: increasing patient pool due to changes in demography and lifestyle

Threat: cost-conscious pricing and reimbursement environment

US

US opportunities

US threats

Japan

Japan opportunities

Japan threats

EU5: opportunities and threats

EU5 Opportunities

EU5 Threats

France: opportunities and threats

France opportunities

France threats

Germany: opportunities and threats

Germany opportunities

Germany threats

Italy: opportunities and threats

Italy opportunities

Italy threats

Spain: opportunities and threats

Spain opportunities

Spain threats

UK: opportunities and threats

UK opportunities

UK threats

Summary of environmental issues affecting the antithrombotic market size

CHAPTER 4 FORECAST ANALYSIS

Key assumptions and events

New products

Future outlook on key marketed products

Lovenox (enoxaparin)

Angiomax (bivalirudin)

Arixtra (fondaparinux)

Plavix (clopidogrel)

GP 2b/3a inhibitors and thrombolytics

Generic incursion: patent expiries and marketing exclusivity

Limitations of data

Forecasts

CHAPTER 5 CASE STUDIES: KEY PIPELINE AGENTS

Case study A – What commercial potential does the oral anticoagulant market segment harbor?

The market opportunity

Warfarin’s monitoring requirement and dosing complexity generates an opening in the market for novel oral anticoagulants

Oral antiplatelets are unlikely to threaten commercial potential of emerging oral anticoagulants

The key competitors in development

The commercial potential of oral anticoagulants

Patient potential of oral anticoagulants

Sales forecast of the two most advanced oral anticoagulants

Conclusions

Case study B – Will prasugrel capture the antiplatelet market?

The market opportunity

The unmet need profile of the antiplatelet market indicates opportunities for novel antiplatelets.

Commercial potential of prasugrel

Drug overview: prasugrel (CS-747)

Sales forecast of prasugrel

APPENDIX A

Bibliography

Report methodology

Standard units

Japanese market data

APPENDIX B – MARKET FORECAST DATA

US forecasts

Japan forecasts

France forecasts

Germany forecasts

Italy forecasts

Spain forecasts

UK forecasts

M5EU forecasts

Global forecasts

About Datamonitor

About Datamonitor Healthcare

About the Cardiovascular Disease analysis team

Disclaimer